Editas Medicine, Inc.
CRISPR/Cas9-Mediated Exon-Skipping Approach for USH2A-Associated Usher Syndrome

Abstract:

Compositions for use in treating subjects with USH2A-associated retinal and/or cochlear degeneration that result from mutations in exon 13 of the USH2A gene by deletion of exon 13 from the USH2A gene or transcripts, and methods of use thereof, as well as genetically modified animals and cells.